Beyond ACE Inhibitors: Exploring the Benefits of Angiotensin Receptor-Neprilysin Inhibitors in Managing HFrEF

Document Type

Article

Publication Title

EC Cardiology

Abstract

Around 115 million people in the US suffer from hypertension, 100 million are obese, 92 million have prediabetes, 26 million have diabetes, and 125 million have atherosclerotic CVD, all of which are high-risk factors that contribute to the development of HF [41]. As a result, a considerable number of the US population can be classified as either at risk of HF or in stage A HF. Common causes of HF include ischemic heart disease, myocardial infarction (MI), hypertension, and valvular heart disease (VHD) [41]. The traditional pharmacotherapy for HF has mainly targeted chronic HF with reduced ejection fraction (HFrEF) and includes angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), β-blockers (BB), and mineralocorticoid receptor antagonists (MRAs). Despite the effectiveness of ACE inhibitors, a new therapy called angiotensin receptor-neprilysin inhibitors (ARNI) have surfaced and demonstrated encouraging outcomes comparable to ACE inhibitors. This poses questions about whether ACE inhibitors or ARNIs are superior in the management of HFrEF. This review focuses on the clinical effectiveness of ACE inhibitors and ARNI in the management of HFrEF.

First Page

1

Last Page

8

Publication Date

2-2024

Comments

Leonard B Goldstein., et al. "Beyond ACE Inhibitors: Exploring the Benefits of Angiotensin Receptor-Neprilysin Inhibitors in Managing HFrEF." EC Cardiology 10.5 (2023): 01-08.

Accepted Version

12 Months embargo, Publisher source must be acknowledged with citation, Must link to publisher version with DOI, Set phrase to accompany archived copy

Link to Full Text

Share

COinS